Format

Send to

Choose Destination
Expert Rev Clin Immunol. 2015;11(9):1015-32. doi: 10.1586/1744666X.2015.1062366. Epub 2015 Jul 9.

Current and emerging treatment options for Wiskott-Aldrich syndrome.

Author information

1
Department of Clinical Immunology and Bone Marrow Transplantation, Great Ormond Street Hospital National Health Service Trust, London WC1N 1JH, UK.

Abstract

Wiskott-Aldrich syndrome is a life-threatening primary immunodeficiency associated with a bleeding tendency, eczema and a high incidence of autoimmunity and malignancy. Stem cell transplantation offers the opportunity of cure for all these complications, and over the past 35 years there has been a remarkable improvement in survival following this treatment. Here, we review advances in management of clinical complications pre- and post-transplant, as well as discuss the morbidity Wiskott-Aldrich syndrome patients experience following treatment. For patients with a poorly matched stem cell donor, recent gene therapy trials demonstrate encouraging results and the potential of low-toxicity therapy for all patients.

KEYWORDS:

Wiskott Aldrich syndrome; Wiskott Aldrich syndrome protein; X-linked thrombocytopenia; allogeneic hematopoietic stem cell transplantation; autoimmunity; gene therapy; primary immunodeficiency; thrombocytopenia

PMID:
26159751
DOI:
10.1586/1744666X.2015.1062366
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center